Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Walsh

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
Plos Medicine|December 6, 2021
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort studyShelly Karuna, Shuying Sue Li, Shannon Grant, et al.
Respiratory Care|June 25, 2024
Perspectives on Using Race in Pulmonary Function Testing: A National Survey Fellows and Program DirectorsDebasree Banerjee, Sara Aijaz, Nicholas J Nassikas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 5, 2011
Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsisLaura E Fredenburgh, Margarita M Suárez Velandia, Jun Ma, et al.
Nature Medicine|October 6, 2022
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trialSpyros Chalkias, Frank Eder, Brandon Essink, et al.
The Journal of Clinical Investigation|December 1, 2021
Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trialSuzanne L Campion, Elena Brenna, Elaine Thomson, et al.
Nature Communications|August 23, 2023
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The New England Journal of Medicine|September 16, 2022
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The Journal of Infectious Diseases|March 14, 2013
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trialStephen R Walsh, Marissa B Wilck, David J Dominguez, et al.
The Lancet. Infectious Diseases|July 10, 2025
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSpyros Chalkias, Patrick Dennis, Dena Petersen, et al.
Vaccine|June 11, 2024
Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine seriesAmy C Sherman, Simon D van Haren, Ella Borberg, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Plos Medicine|December 6, 2021
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort studyShelly Karuna, Shuying Sue Li, Shannon Grant, et al.
Respiratory Care|June 25, 2024
Perspectives on Using Race in Pulmonary Function Testing: A National Survey Fellows and Program DirectorsDebasree Banerjee, Sara Aijaz, Nicholas J Nassikas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 5, 2011
Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsisLaura E Fredenburgh, Margarita M Suárez Velandia, Jun Ma, et al.
Nature Medicine|October 6, 2022
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trialSpyros Chalkias, Frank Eder, Brandon Essink, et al.
The Journal of Clinical Investigation|December 1, 2021
Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trialSuzanne L Campion, Elena Brenna, Elaine Thomson, et al.
Nature Communications|August 23, 2023
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The New England Journal of Medicine|September 16, 2022
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The Journal of Infectious Diseases|March 14, 2013
Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trialStephen R Walsh, Marissa B Wilck, David J Dominguez, et al.
The Lancet. Infectious Diseases|July 10, 2025
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSpyros Chalkias, Patrick Dennis, Dena Petersen, et al.
Vaccine|June 11, 2024
Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine seriesAmy C Sherman, Simon D van Haren, Ella Borberg, et al.
Pageof 8